Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors

L’objectif de cette étude internationale est d’essayer d’identifier les patients à risques de développer des toxicités tardives secondaires à leur radiothérapie


REQUITE on Facebook

Abstract accepted for poster presentation at the 15th St.Gallen International Breast Cancer Conference in Vienna.

The REQUITE abstract: "T. Rattay, et al: Development and validation of a predictive risk model for acute skin toxicity in patients undergoing breast radiotherapy" has been accepted for poster presentation at the 15th St. Gallen International Breast Cancer Conference, Primary Therapy of Early Breast Cancer Vienna, Austria 15-18 March 2017.

Tim Rattay is investigating how clinical and genetic data can be integrated to give breast cancer patients more accurate information about their individual risk of radiation side-effects.

REQUITE review article in Radiotherapy & Oncology now available online.

The review article: "Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement" by Dirk De Ruysscher, Gilles Defraene, Bram L.T. Ramaekers, Philippe Lambin, Erik Briers, Hilary Stobart, Tim Ward, Søren M Bentzen, Tjeerd van Staa, David Azria, Barry Rosenstein, Sarah Kerns and Catharine West, is now available online.

Older news




5th Annual REQUITE Consortium Meeting and 9th Annual Radiogenomics Consortium Meeting

The 5th REQUITE Annual Consortium Meeting will be held 20-21st June 2017 at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain As in previous years, this will be held in conjunction with the International Radiogenomics Consortium annual meeting on 19th June.

Monday, 19 June, 2017 to Wednesday, 21 June, 2017
Vall d’Hebron Institute of Oncology (VHIO), CELLEX CENTER
C/ Natzaret, 115-117
08035 Barcelona